Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paola S. Dal Cin, Ph.D.

Co-Author

This page shows the publications co-authored by Paola Dal Cin and Valentina Nardi.
Connection Strength

1.271
  1. N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL). Genes Chromosomes Cancer. 2022 Feb 25.
    View in: PubMed
    Score: 0.247
  2. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2022 01 08; 6(3):818-827.
    View in: PubMed
    Score: 0.245
  3. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Adv. 2020 02 11; 4(3):445-448.
    View in: PubMed
    Score: 0.215
  4. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111.
    View in: PubMed
    Score: 0.213
  5. Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Am J Hematol. 2015 Jun; 90(6):529-33.
    View in: PubMed
    Score: 0.154
  6. Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica. 2021 02 01; 106(2):555-564.
    View in: PubMed
    Score: 0.057
  7. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020 07 14; 4(13):3136-3140.
    View in: PubMed
    Score: 0.055
  8. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol. 2018 Feb 01; 4(2):235-238.
    View in: PubMed
    Score: 0.047
  9. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015 Apr; 28(4):552-63.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.